Virbac SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0000031577
EUR
339.00
-1.5 (-0.44%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

7.31 k

Shareholding (Dec 2023)

FII

0.01%

Held by 1 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 24.65

 
2

Healthy long term growth as Operating profit has grown by an annual rate 10.75%

 
3

Flat results in Dec 24

4

With ROE of 12.82%, it has a Fair valuation with a 2.51 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 2,995 Million ()

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.41%

stock-summary
Debt Equity

0.16

stock-summary
Return on Equity

12.82%

stock-summary
Price to Book

2.81

Revenue and Profits:
Net Sales:
166 Million
(Quarterly Results - Dec 2012)
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.83%
0%
3.83%
6 Months
6.27%
0%
6.27%
1 Year
4.79%
0%
4.79%
2 Years
14.72%
0%
14.72%
3 Years
37.53%
0%
37.53%
4 Years
-22.07%
0%
-22.07%
5 Years
54.09%
0%
54.09%

Virbac SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
8.50%
EBIT Growth (5y)
10.75%
EBIT to Interest (avg)
24.65
Debt to EBITDA (avg)
0.10
Net Debt to Equity (avg)
0.13
Sales to Capital Employed (avg)
1.20
Tax Ratio
26.05%
Dividend Payout Ratio
8.36%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
22.13%
ROE (avg)
16.62%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
2.51
EV to EBIT
14.32
EV to EBITDA
10.92
EV to Capital Employed
2.30
EV to Sales
1.98
PEG Ratio
NA
Dividend Yield
0.46%
ROCE (Latest)
16.02%
ROE (Latest)
12.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Virbac SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.07% vs 2.52% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 20.40% vs -0.16% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,397.40",
          "val2": "1,246.90",
          "chgp": "12.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "274.80",
          "val2": "219.50",
          "chgp": "25.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "11.10",
          "val2": "8.90",
          "chgp": "24.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-14.30",
          "val2": "5.60",
          "chgp": "-355.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "145.80",
          "val2": "121.10",
          "chgp": "20.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "155.70%",
          "val2": "137.90%",
          "chgp": "1.78%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,397.40
1,246.90
12.07%
Operating Profit (PBDIT) excl Other Income
274.80
219.50
25.19%
Interest
11.10
8.90
24.72%
Exceptional Items
-14.30
5.60
-355.36%
Consolidate Net Profit
145.80
121.10
20.40%
Operating Profit Margin (Excl OI)
155.70%
137.90%
1.78%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 12.07% vs 2.52% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 20.40% vs -0.16% in Dec 2023

stock-summaryCompany CV
About Virbac SA stock-summary
stock-summary
Virbac SA
Pharmaceuticals & Biotechnology
Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.
Company Coordinates stock-summary
Company Details
13eme rue LID, Bp 27, Carros Cedex , CARROS None : 06510
Registrar Details